{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:09:03Z","timestamp":1794712143607,"version":"4.9.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ministry of Health, Labor, and Welfare of Japan","award":["H30-menneki-shitei-002"],"award-info":[{"award-number":["H30-menneki-shitei-002"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labor, and Welfare of Japan","doi-asserted-by":"publisher","award":["H30-menneki-shitei-002"],"award-info":[{"award-number":["H30-menneki-shitei-002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate clinical characteristics and time course of lymphoproliferative disorders (LPDs) in rheumatoid arthritis (RA) patients after methotrexate (MTX) discontinuation, in those who achieved spontaneous regression (SR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively reviewed clinical data from RA patients with LPDs obtained from eight institutions between 2000 and 2017 and compared clinical and pathological findings between SR and non-SR groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 232 RA patients with LPDs, 216 were treated with MTX at the onset of LPD and 144 (66.7%) achieved SR after MTX discontinuation. Higher MTX doses, high titers of anti-CCP antibodies (&amp;gt;13.5\u2009U\/mL), and lower LDH and soluble IL-2 receptor levels were associated with SR. Lymphocyte count was decreased at LPD onset and increased at 2 weeks after MTX discontinuation in the SR group. Epstein\u2013Barr virus-positive mucocutaneous ulcer, reactive lymphoid hyperplasia and unclassifiable B-cell lymphoma, were more frequent in the SR than in the non-SR group. In multivariable analysis, diffuse large B-cell lymphomas was an independent predictive factor for non-SR. In the patients with SR, 73.9% achieved partial or complete regression as early as 2 weeks after MTX discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SR and non-SR in RA patients with LPDs after MTX discontinuation were associated with certain clinical characteristics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1080\/14397595.2021.1879362","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T12:02:01Z","timestamp":1611662521000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":35,"title":["Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case\u2013control study"],"prefix":"10.1093","volume":"32","author":[{"given":"Nobuo","family":"Kuramoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-1984","authenticated-orcid":false,"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan"},{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"},{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"},{"name":"Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakano","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"},{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"},{"name":"Tobata General Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Tokai University Hachioji Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"},{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology"},{"name":"Division of Rheumatology, Tokai University Hachioji Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"6","key":"2022010903465650000_R1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2022010903465650000_R2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"issue":"2","key":"2022010903465650000_R3","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol"},{"issue":"1","key":"2022010903465650000_R4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"issue":"7","key":"2022010903465650000_R5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am J Sug Pathol"},{"issue":"5","key":"2022010903465650000_R6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/10428194.2017.1369073","article-title":"Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression","volume":"59","author":"Tokuhira","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2022010903465650000_R7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2022010903465650000_R8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2022010903465650000_R9","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3109\/10428194.2015.1022769","article-title":"Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal","volume":"56","author":"Inui","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2022010903465650000_R10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/rheumatology\/kex002","article-title":"Distinct pattern of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate","volume":"56","author":"Saito","year":"2017","journal-title":"Rheumatology"},{"issue":"5","key":"2022010903465650000_R11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022010903465650000_R12","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/acr.22306","article-title":"Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients","volume":"66","author":"Kameda","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2022010903465650000_R13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2022010903465650000_R14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med Oncol"},{"issue":"5","key":"2022010903465650000_R15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14397595.2016.1259714","article-title":"Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents","volume":"27","author":"Katsuyama","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"4","key":"2022010903465650000_R16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14397595.2017.1387223","article-title":"Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome","volume":"28","author":"Tsukui","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"2","key":"2022010903465650000_R17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J Rheumatol"},{"key":"2022010903465650000_R18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2018.00621","article-title":"Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment","volume":"9","author":"Saito","year":"2018","journal-title":"Front Immunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1080\/14397595.2021.1879362\/41812066\/1879362.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/24\/42083519\/1879362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/24\/42083519\/1879362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:55:57Z","timestamp":1642560957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/1\/24-31\/6468895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,8]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2021.1879362","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}